Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 81 Leukemia 41 Gastrointestinal Stromal Tumors 32 Precursor Cell Lymphoblastic Leukemia-Lymphoma 30 Leukemia, Myeloid, Chronic-Phase 27 Blast Crisis 13 Neoplasms 10 Neoplasm Metastasis 10 Melanoma 10 Brain Neoplasms 10 Lung Neoplasms 9 Prostatic Neoplasms 8 Leukemia, Myeloid, Acute 8 Gliosarcoma 8 Glioblastoma 8 Leukemia, Myeloid, Accelerated Phase 7 Glioma 6 Carcinoma, Non-Small-Cell Lung 6 Sarcoma 5 Philadelphia Chromosome 5 Oligodendroglioma 5 Recurrence 4 Primary Myelofibrosis 4 Polycythemia Vera 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Head and Neck Neoplasms 4 Central Nervous System Neoplasms 4 Breast Neoplasms 4 Astrocytoma 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Imatinib Mesylate × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡